Eli Lilly and Company (NYSE:LLY) Receives Consensus Rating of “Moderate Buy” from Brokerages

Eli Lilly and Company (NYSE:LLY) has earned an average rating of “Moderate Buy” from the thirty research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $1,305.25.

LLY has been the topic of a number of recent research reports. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Berenberg Bank set a $1,400.00 price objective on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Sanford C. Bernstein boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Finally, Truist Financial upped their target price on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a report on Friday, August 7th.

Eli Lilly and Company Stock Up 0.5%

Shares of LLY stock opened at $1,171.09 on Friday. Eli Lilly and Company has a one year low of $712.05 and a one year high of $1,292.65. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a fifty day moving average price of $1,176.84 and a 200 day moving average price of $1,079.50. The stock has a market cap of $1.10 trillion, a P/E ratio of 39.30, a price-to-earnings-growth ratio of 1.44 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts predict that Eli Lilly and Company will post 36.54 earnings per share for the current year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last three months. 0.14% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its position in shares of Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Silicon Valley Capital Partners raised its position in Eli Lilly and Company by 3.7% in the 2nd quarter. Silicon Valley Capital Partners now owns 13,489 shares of the company’s stock worth $16,179,000 after purchasing an additional 480 shares during the last quarter. Security National Bank of Sioux City Iowa IA acquired a new position in Eli Lilly and Company during the 2nd quarter worth $120,000. Wellington Altus USA Inc. lifted its holdings in Eli Lilly and Company by 38.2% during the 2nd quarter. Wellington Altus USA Inc. now owns 311 shares of the company’s stock worth $373,000 after buying an additional 86 shares in the last quarter. Finally, Bullseye Investment Management LLC bought a new position in Eli Lilly and Company in the 2nd quarter valued at $2,527,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly broke ground on a planned $6.5 billion manufacturing facility in Houston that will produce active pharmaceutical ingredients for medicines including the Foundayo obesity pill. The site is expected to create more than 600 jobs and strengthen Lilly’s U.S. supply chain as demand for GLP-1 treatments grows. Eli Lilly Breaks Ground On $6.5 Billion Houston Manufacturing Facility
• Positive Sentiment: CEO David Ricks said approximately 700,000 seniors have started GLP-1 medicines since Medicare coverage began, with Lilly capturing about 70% of new senior patients. Foundayo also accounts for roughly one-third of new oral GLP-1 prescriptions, suggesting strong early adoption of Lilly’s pill franchise. Eli Lilly CEO says 700,000 new seniors have started GLP-1s
• Positive Sentiment: The FDA granted full approval to Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer. The treatment was reported to double progression-free survival, adding another commercial opportunity beyond Lilly’s obesity and diabetes portfolio. Eli Lilly Gets Full FDA Approval for Inluriyo
• Positive Sentiment: Analyst sentiment remains supportive: Lilly is rated a consensus Moderate Buy, with rising price targets and a larger GLP-1 market share than Novo Nordisk. Investor Ken Langone also publicly expressed confidence that LLY could eventually reach $2,000, although such commentary is not a fundamental catalyst. Eli Lilly’s Tough Month
• Neutral Sentiment: Lilly indicated interest in purchasing up to $100 million of Oura shares in the company’s IPO. The investment could support LillyDirect’s use of wearable health data for patients taking GLP-1 therapies, but it is unlikely to materially affect Lilly’s near-term earnings. Oura’s $15.6 Billion IPO
• Negative Sentiment: Competition is intensifying. Viking Therapeutics shares surged after data showed its VK2735 could maintain weight loss with less-frequent injections, while Novo Nordisk’s CagriSema outperformed a lower 5-milligram tirzepatide dose in a diabetes study. These developments raise longer-term risks to Zepbound’s market share, pricing and chronic-treatment economics. Viking Therapeutics Skyrockets on Obesity Drug Data

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company’s products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer’s disease.